Drug intelligence / Profile preview

baclofen + botulinum toxin type A

Development stage
Unknown
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Oral, Intrathecal, Intramuscular
01

Overview

Baclofen + botulinum toxin type A is a combination therapy used primarily for the management of spasticity, particularly in conditions such as cerebral palsy, spinal cord injury, and other neurological disorders. Baclofen is a centrally acting muscle relaxant and GABA-B receptor agonist that reduces spasticity by inhibiting excitatory neurotransmitter release in the central nervous system. Botulinum toxin type A is a neurotoxin that acts peripherally at the neuromuscular junction to inhibit acetylcholine release, resulting in localized muscle relaxation and reduction of focal spasticity. The combination leverages both systemic (baclofen) and local (botulinum toxin) mechanisms to provide comprehensive control of muscle tone abnormalities, improve pain, quality of life, self-care ability, and facilitate rehabilitation programs[1][2][4][7][8].

02

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)SNAP25 (Synaptosome-associated protein 25)Muscle-type nicotinic acetylcholine receptorGABRB2 (GABA-A receptor subunit beta-2)

Beyond the preview

Go deeper on baclofen + botulinum toxin type A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on baclofen + botulinum toxin type A.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call